• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » M&A: Spectranetics prepares $200M offering to fund $230M AngioScore bid

M&A: Spectranetics prepares $200M offering to fund $230M AngioScore bid

May 28, 2014 By Arezu Sarvestani

M&A: Spectranetics prepare $200M offering to fund $230M AngioScore bid

Spectranetics (NSDQ:SPNC) announced this week that it plans to launch a senior note funding round in order to support its $230 million bid to acquire AngioScore and its portfolio of angioplasty catheters.

Spectranetics plans to offer $200 million in convertible senior notes due 2034, and expects to grant underwriters a 30-day option to purchase up to $30 million more.

The funds will help Spectranetics finance the acquisition, which consists of $115 million in cash and $115 million in Spectranetics common stock, with additional payouts pending certain regulatory and commercial achievements.

Sign up to get our
free newsletters delivered right to your inbox.

The AngioScore buy fits snugly within Spectranetics’ growth strategy, according to Spectranetics president & CEO Scott Drake.

"AngioScore meets our criteria with an exceptional strategic fit, leverageable call points, differentiated technology and clear operating efficiencies,” Drake said in prepared remarks. "As a combined entity, we expect to have a meaningfully expanded market opportunity and a compelling product portfolio.”

“Simply put, we are ‘better together’,” AngioScore president & CEO Thomas Trotter added. “We believe that this combination provides an opportunity to build a remarkable future while delivering life-impacting technologies to physicians and patients. In Spectranetics, we find a like-minded partner that shares our values, our commitment to improving patients’ lives, and equally high standards for operational excellence and quality.”

Together the companies accounted for pro forma revenues of $213.5 million in 2013, and Spectranetics expects the acquisition to be accretive to adjusted earnings starting in 2015.

Filed Under: Catheters, Funding Roundup, Mergers & Acquisitions, News Well Tagged With: AngioScore Inc., Spectranetics Corp.

More recent news

  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out
  • Former Masimo COO is joining BD to run Connected Care

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy